Find a Clinical Trial

Showing 111 - 120 of 171 Trials

Randomized Study of ONC-392 plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) who Progressed on Androgen Receptor (AR) Pathway Inhibition

Principal Investigator:

Mark N. Stein, MD

Contact Number:

212-342-5162

NCT Number:

NCT05682443

Population:

Adult

Phase:

I/II

The main purpose of the study is to determine whether the study drug, ONC-392, together with a standard of care drug PLUVICTO® (Lutetium Lu 177 Vipivotide Tetraxetan), are safe and well tolerated, and whether two drugs are effective in treating prostate cancer, in comparison with the standard of care PLUVICTO® alone. ONC-392 has not yet been approved by the Food and Drug Administration (FDA). PLUVICTO® is FDA approved but is not approved to be combined with ONC-392. Are you Eligible? (Inclusion Criteria) Male 18 years or older -Confirmed prostate adenocarcinoma -Have had previous...
An Open-Label, Multicenter Study of LY4050784, a Selective SMARCA2/BRM Inhibitor, inAdvanced Solid Tumor Malignancies with SMARCA4/BRG1 Alterations- J5M-OX-JOXA

Principal Investigator:

Benjamin Herzberg, MD

Contact Number:

212-342-5162

NCT Number:

NCT06561685

Population:

Adult

Phase:

I

The purpose of this study is to test the safety of an investigational treatment called LY4050784 in subjects with solid tumors that have a particular genetic abnormality (called an alteration or mutation) of a gene called SMARCA4 and/or BRG1. LY4050784 is an investigational (or experimental) drug, taken by mouth that targets a gene called SMARCA2/BRM, and may treat certain cancers. Investigational means neither the FDA nor any other health or regulatory authority in other countries have approved LY4050784. This study will be the first time LY4050784 will be tested in humans. Are you Eligible...
A Phase 1a/1b Study of the pan-KRAS Inhibitor LY4066434 in Participants with KRAS Mutant SolidTumors

Principal Investigator:

Benjamin Herzberg, MD

Contact Number:

212-342-5162

NCT Number:

NCT06607185

Population:

Adult

Phase:

I

This research study is being done to test the safety of an investigational treatment called LY4066434 when given alone or with other cancer drugs. LY4066434 is an investigational (or experimental) drug, taken orally. It was designed for patients that have abnormalities (also known as DNA mutations) in the KRAS gene that can occur in some types of cancer. LY4066434 is not approved by the U.S. Food and Drug Administration. Are you Eligible? (Inclusion Criteria) Must be ≥18 years of age, 2. Must be able to swallow tablets. 3. Must be able to comply with outpatient treatment, laboratory...
A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-cancer Agents in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

Principal Investigator:

Hua-Jay J Cherng, MD

Contact Number:

212-342-5162

NCT Number:

NCT04970901

Population:

Adult

Phase:

I

This study will look at the safety, effectiveness (efficacy) and tolerability of an investigational drug called loncastuximab tesirine in combination with other anti-cancer drugs polatuzumab vedotin, glofitamab and mosunetuzumab for patients with relapsed or refractory B-cell Non- Hodgkin Lymphoma. Loncastuximab tesirine is an antibody drug conjugate (ADC), which is a type of medicine that combines an antibody (a protein that binds to specific substances in the body) with a chemotherapy drug that can kill cells. The antibody part of the study drug potentially helps direct the chemotherapy to...
A Phase 1 Open-label, Multicenter Study Evaluating theSafety and Efficacy of KITE-363 or KITE-753, AutologousAnti-CD19/CD20 CAR T-cell Therapies, in Subjects WithRelapsed and/or Refractory B-cell Lymphoma

Principal Investigator:

Ran Reshef, MD, MSc

Contact Number:

212-342-5162

NCT Number:

NCT04989803

Population:

Adult

Phase:

I

You have been invited to participate in this study because you have relapsed and/or refractory B-cell lymphoma and standard therapies available to treat your disease have limited effectiveness. The purpose of this study is to find out if the experimental products, KITE-363 and KITE-753, are safe and effective in treating your relapsed and/or refractory B-cell lymphoma. Participants will receive either KITE-363 or KITE-753 one time through into the vein (IV) infusion. The experimental treatment would involve removing some of your immune cells, genetically engineering those cells to identify...
An open-label, multi-center, non-randomized phase I dose escalation study to investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 given as monotherapy in patients with relapsed or refractory T-cell Lymphoma

Principal Investigator:

Barbara Pro, MD

Contact Number:

212-342-5162

NCT Number:

NCT05079282

Population:

Adult

Phase:

I

The purpose of this study is to find out the safety, effectiveness, and blood levels of various doses of the study drug in participants with T-cell lymphoma that has not improved or has gotten worse. ONO-4685 is an experimental drug which is not approved by Health Authorities including United States Food and Drug Administration (FDA). The study drug is a protein made in laboratory called an antibody. Antibodies are made naturally in our body and are a key part of our immune system. The study drug antibody targets 2 specific proteins: a protein called PD-1 on cancer cells and protein Are you...
An open-label, Phase 1b study to evaluate the safety andtolerability of eflornithine plus temozolomide in patients with newly diagnosed glioblastoma or astrocytoma

Principal Investigator:

Maria Diaz Ordonez, MD

Contact Number:

212-342-5162

NCT Number:

NCT05879367

Population:

Adult

Phase:

I

The purpose of this study is to measure how safe eflornithine is in combination with temozolomide in patients with newly diagnosed glioblastoma multiforme (GBM) following radiation therapy. Safety and tolerability will be determined on the basis of physical exams, laboratory tests, and questions about any problems you might experience during the study.This study will also measure levels of eflornithine in patients following dosing, and it will evaluate how effective eflornithine is as a treatment of GBM when combined with temozolomide. Eflornithine is an experimental drug, which means that it...
A PHASE 1A/B OPEN-LABEL MASTER STUDY OF PF-07799544 AS ASINGLE-AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTSIN PARTICIPANTS WITH BRAF-MUTANT MELANOMA AND OTHER SOLID TUMORS

Principal Investigator:

Aya Haggiagi, MD

Contact Number:

212-342-5162

NCT Number:

NCT05538130

Population:

Adult

Phase:

I

The purpose of this study is to learn about the safety (the impact of the study drug on your body) and the effects of study drug PF-07799544 for specific types of cancer on the body and to find the best dose for treating certain cancers. For BRAF (B-raf proto-oncogene serine/threonine kinase) mutated solid tumors, PF-07799544 may be combined with encorafenib, also known as BRAFTOVI® (an FDA approved cancer medication). The study drug PF-07799544 is an investigational drug because it is not FDA approved for use in this country. The study drug encorafenib is approved in this country and is...
A Phase 1a/1b Trial in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma to Determine the Safety Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, a fenretinide phospholipid suspension (12.5 mg/mL) for Intravenous Infusion

Principal Investigator:

Barbara Pro, MD

Contact Number:

212-342-5162

NCT Number:

NCT04234048

Population:

Adult

Phase:

I

The purpose of this study is to see what effects, good and/or bad, the study drug, ST-001, has on you and your cancer, to find the best dose for treating your condition, and to see how safe ST-001 is for participants with your condition. This study will help us understand more about whether intravenous (injected into the vein) ST-001, will be a useful study treatment for subjects with Relapsed/Refractory T-cell Non-Hodgkin Lymphoma (T-Cell NHL). Relapsed or refractory disease means your disease that has come back after initial treatment or did not respond to initial treatment. Approximately...
A Phase 1/1b Study of ASP2138 as Monotherapy and in Combination with Pembrolizumab and mFOLFOX6 or Ramucirumab and Paclitaxel in Participants with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in

Principal Investigator:

Ryan H. Moy, MD, PhD

Contact Number:

212-342-5162

NCT Number:

NCT05365581

Population:

Adult

Phase:

I

The goal of this study is to see if a study drug called ASP2138 is safe and effective for people diagnosed with tumors known to have Claudin (CLDN) 18.2 expression. CLDN is a group of proteins seen in gastric-specific, gastroesophageal junction (GEJ) or pancreatic cancer types. The study will also see how ASP2138 is processed in the blood. Each participant will complete a number of procedures and blood collections in order to find the best dose of ASP2138. When this dosage is identified, it will be used to evaluate if ASP2138 causes tumors to shrink. ASP2138 will be assessed continuously...

Find a Clinical Trial

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Pages